Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE. Schaapveld M, et al. Among authors: zijlstra jm. N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949. N Engl J Med. 2015. PMID: 26699166 Free article.
[Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
Visser OJ, Zijlstra JM, van Dongen GA, Huijgens PC. Visser OJ, et al. Among authors: zijlstra jm. Ned Tijdschr Geneeskd. 2005 Oct 15;149(42):2324-8. Ned Tijdschr Geneeskd. 2005. PMID: 16261710 Review. Dutch.
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Vellenga E, et al. Among authors: zijlstra jm. Blood. 2008 Jan 15;111(2):537-43. doi: 10.1182/blood-2007-08-108415. Epub 2007 Oct 30. Blood. 2008. PMID: 17971487 Free article. Clinical Trial.
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma.
De Bruin ML, Burgers JA, Baas P, van 't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Aleman BM, van Leeuwen FE. De Bruin ML, et al. Among authors: zijlstra jm. Blood. 2009 Apr 16;113(16):3679-81. doi: 10.1182/blood-2008-10-184705. Epub 2009 Feb 20. Blood. 2009. PMID: 19234144 Free article.
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GA, Lubberink M. Rizvi SN, et al. Among authors: zijlstra jm. Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):512-20. doi: 10.1007/s00259-011-2008-5. Epub 2012 Jan 5. Eur J Nucl Med Mol Imaging. 2012. PMID: 22218876 Free PMC article. Clinical Trial.
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Wondergem MJ, Zijlstra JM, de Rooij M, Visser OJ, Huijgens PC, Zweegman S. Wondergem MJ, et al. Among authors: zijlstra jm. Br J Haematol. 2012 May;157(3):395-7. doi: 10.1111/j.1365-2141.2011.08991.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22224561 Free article. No abstract available.
153 results